MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine"

  • 2024 International Congress

    Clinical Response and Reduction in Medication Use After Deep Brain Stimulation Surgery in a Cohort of Parkinson’s Disease Patients in Colombia

    T. Lopez Gonzalez, S. Poveda, M. Fonseca, P. Arango, O. Rojas, G. Monsalve, JC. Diez, J. Lobato, O. Bernal Pacheco (Bogotá, Colombia)

    Objective: The objective is to investigate the clinical outcomes and subsequent use of medications in a group of Colombian Patients with DBS Surgery. Background: Parkinson's…
  • 2024 International Congress

    Pathological Mechanisms Associated with Atrazine-Induced Parkinson’s Disease Pathogenesis in Rat Model: The Rescue Role of Myricetin

    C. Ikeji, E. Farombi (Ibadan, Nigeria)

    Objective: This study aimed at investigating the mechanisms involved in the pathogenesis of Parkinson’s Disease in atrazine rat model of Parkinson’s Disease and the neuroprotective…
  • 2024 International Congress

    The Impact of Drug Interactions on the results of DAT-SPECT Imaging in a Specialty Movement Disorders Practice: A Retrospective Analysis of Outcomes

    I. Kang, D. Bega (Chicago, USA)

    Objective: This study was a retrospective chart review of patients who underwent DAT-SPECT imaging for parkinsonism while on drugs listed as potentially interacting with the…
  • 2024 International Congress

    Effects of striatal dopamine depletion and altered brain metabolism on Parkinson’s disease

    HS. Yoo, PH. Lee, CH. Lyoo (Seoul, Republic of Korea)

    Objective: To investigate the relationship between striatal dopamine depletion, altered brain metabolism, motor deficits, and cognitive dysfunction in Parkinson’s disease (PD) Background: PD shows degeneration…
  • 2024 International Congress

    Eye Blink Rate and Putamen DaTScan Covariation in Parkinson’s Disease

    Q. Salardaine, V. Vasudevan, N. Villain, E. Biondetti, S. Lehéricy, M. Vidailhet, P. Pouget (Paris, France)

    Objective: To examine the relationship between blink rate and DaTScan in Parkinson’s disease. Background: Spontaneous eye-blink rate (BR) is blinking without external triggers. Parkinson's disease…
  • 2024 International Congress

    Metabolic Covariance Networks in Progressive Supranuclear Palsy Revealed by Spatial independent component analysis

    B. Wang, H. Wang, W. Luo (Hangzhou, China)

    Objective: The study aims to apply S-ICA to 18F-fluorodeoxyglucose (FDG) data in progressive supranuclear palsy (PSP) patients,  identifing PSP-specific independent metabolic covariate networks. We also…
  • 2024 International Congress

    Putaminal dopamine modulates movement motivation in Parkinson’s disease

    M. Banwinkler, V. Dzialas, L. Rigoux, H. Theis, A. Asendorf, K. Giehl, M. Tittgemeyer, M. Hoenig, T. van Eimeren (Cologne, Germany)

    Objective: To investigate the quantitative effect of dopamine depletion on the motivation of motor effort in Parkinson’s disease. Background: The relative inability to produce effortful…
  • 2024 International Congress

    Dopaminergic alterations in patients with Alzheimer’s disease

    M. Azharuddin, M. Sharma (New Delhi, India)

    Objective: The objective of this study was to conduct a meta-analysis to determine the pooled mean difference (MD) in dopaminergic measures between Alzheimer’s disease and…
  • 2024 International Congress

    Criteria Defining Chronic Pain Associated with Parkinson Disease

    S. Perez-Lloret, J. Hunger, J. Bally, G. Kägi, J. Möller, N. Hollenstein, R. Gonzenbach, F. Brugger, D. Ciampi-de-Andrade, V. Mylius (Buenos Aires, Argentina)

    Objective: To assess the factors defining the association of chronic pain (>3 months) with PD. Background: Non-motor symptoms can be often associated with Parkinson disease…
  • 2024 International Congress

    Comorbidity of schizophrenia and Parkinson’s disease: a clinical case report

    M. Khommyatov, M. Samushiya, I. Smolentseva, S. Kryzhanovskiy (Moscow, Russian Federation)

    Objective: To describe the case of a patient with paranoid schizophrenia followed by the onset of the Parkinson’s disease at the 44-year age Background: Currently…
  • 1
  • 2
  • 3
  • …
  • 24
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #25676 (not found)
  • Crack Dancing: An Uncommon Drug-Induced Chorea
  • #24376 (not found)
  • #24970 (not found)
  • Welcome to the MDS Abstracts Site
  • Effect of marijuana on Essential Tremor: A case report
  • Advanced Search
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley